Clinical trials: Primary Cancer of the Peritoneum
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00303888
- Testing
- docetaxel, idronoxil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Yale University
Ovarian Cancer
The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer
Niraparib is a potent and highly selective PARP-1/-2 inhibitor. The primary objective of this trial is to evaluate the pharmacokinetic (PK) properties of ZL-2306 (niraparib) and its metabolite M1 in patients from Mainland China…
- Trial name
- NCT03551171
- Testing
- ZL-2306 (niraparib)
- Where
- 6 sites in China
- Volunteers
- 42 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
This phase I/II trial is studying the side effects and best dose of viral therapy in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that did not respond to platinum…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00602277
- Testing
- Laboratory Biomarker Analysis, Wild-type Reovirus
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
This study will investigate the efficacy as well as the safety of RAD001 in combination with bevacizumab for recurrent ovarian, peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- RADBEV (NCT01031381)
- Testing
- RAD001, bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Ovarian Cancer, Fallopian Tube Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : alone or, combined with cemiplimab (also known as REGN2810) or, combined with both cemiplimab and fianlimab (also known as REGN3767), or combined with ubamatamab…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT04590326
- Testing
- REGN5668, Cemiplimab, Ubamatamab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 612 people
- Sponsor
- Regeneron Pharmaceuticals
Fallopian Tube Cancer, Ovarian Cancer
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00017017
- Testing
- paclitaxel poliglumex
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
This is a Phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of BAT8006 in subjects with platinum resistance ovarian cancer
- Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06545617
- Testing
- BAT8006 for Injection
- Sponsor
- Bio-Thera Solutions
Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/IIa trial studies the side effects and best dose of a type of specialized immune cell (natural killer cell-like cytotoxic T-lymphocytes (CTLs) (nCTLs) and how well they work when given with a vaccine (alpha-type-1…
- Conditions
- Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage IIA Fallopian Tube Cancer AJCC v8
- Trial name
- NCT03735589
- Testing
- Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body.
- Conditions
- Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
- Trial name
- NCT00072566
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms, Ovarian Cancer
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Background: 18F-CP18 is a chemical designed for use in imaging studies. It is attracted to tumor cells that are being killed by cancer treatment.
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Fallopian Tube Neoplasms, Fallopian Tube Cancer
- Trial name
- NCT01766622
- Testing
- [18F]-CP18, PET/ CT
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00748527
- Testing
- carboplatin, decitabine
- Where
- 11 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- Cancer Research UK
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00006041
- Testing
- MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, QS21
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasm, Ovarian, Fallopian Tube Cancer
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001.
- Conditions
- Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary
- Trial name
- NCT05538624
- Testing
- AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Avenge Bio, Inc
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or…
- Trial name
- NCT00005836
- Testing
- oxaliplatin
- Where
- 74 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma
- Trial name
- NCT02419495
- Testing
- Capecitabine, Carboplatin, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 221 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Peritoneal Cancer
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity.
- Trial name
- NCT00461786
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after…
- Trial name
- NCT02132988
- Testing
- OPT-822/OPT-821
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Mackay Memorial Hospital
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride, carboplatin, and bevacizumab in treating patients with ovarian cancer, primary…
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma
- Trial name
- NCT01459380
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)